Abstracts from 2014 through the most recent CROI can be viewed in this searchable database once they have been presented at the conference. Abstract Contents: The searchable database includes abstract text as submitted by the authors prior to CROI. Study data might be updated during the presentation at CROI. Please refer to the electronic poster or webcast for updates. Searching the Abstract Database: Enter the criteria below and click the “Search” button. After the search has been entered, the results will appear below the search form.
CROI conference materials (eg, the conference program, Abstract eBook, electronic posters, CROI logo, etc) are protected by copyright. Permission to replicate or reproduce these elements, in whole or in part, must be obtained from the CROI Conference Manager, the International Antiviral Society-USA (IAS-USA). Study data (including figures within abstracts or electronic posters) are the property of the study authors. Permission to use data and figures cannot be given by IAS–USA unless it is for regulatory reasons. For more information, please email CROIabstracts@iasusa.org.
1277 Results
Background Long-term tenofovir-containing antiretroviral therapy (ART) achieves durable suppression of HIV and HBV, but its effect on functional cure of HBV infeciton in people with HIV (PWH) remains unclear. We aimed to determine the incidence of and factors associated with hepatitis B surface antigen (HBsAg) loss after treatment with tenofovir-containing ART in HBV-coinfected PWH. Methods…
Background Although sustained virologic response (SVR) following direct-acting antiviral (DAA) therapy is a key goal in treating hepatitis C, some patients continue to experience liver disease progression despite HCV clearance. Metabolic dysfunction-associated steatotic liver disease (MASLD) may contribute to this progression. This study aims to characterize the lipidomic profiles linked to MASLD in HIV/HCV-coinfected patients…
Background Treatment including tenofovir disoproxil (TDF) or alafenamide (TAF) is the standard of care in people living with HIV/HBV infection. Serum HBV-RNA is an emerging biomarker reflecting the activity of intrahepatic HBV reservoir. The aim of the study was to describe HBV seroconversion (HBV-S) rate in HIV/HBV subjects on HBV-active therapy and to analyse markers…
Background Eliminating HCV requires curing people and ensuring they remain free of re-infection. People who inject drugs (PWID) are particularly vulnerable to re-infection, but few re-infection estimates are available from resource-limited settings. We evaluate HCV re-infection rates among PWID treated in community-based centers in 7 Indian cities. Methods From 2021-2022, 3000 PWID ≥18 years with…
Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent comorbidity in people with HIV (PWH). Gut microbiota profiles such as lower diversity and/or alterations in microbiota community structure, have been variably associated with MASLD in people with and without HIV. Recent murine models of metabolic diseases, including MASLD, demonstrated beneficial effects of semaglutide on…
Background Plasma extracellular vesicles (pEV) play a role modulating the immune response. In HIV/HCV coinfection, NK cells are crucial in eliminating activated hepatocellular stellate cells, responsible for progression to liver fibrosis (LF). We previously showed that in individuals with advanced LF (F4), NK cells presented an exhausted phenotype and impaired functionality even after elimination of…
Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is a key risk factor for cardiovascular disease (CVD), potentially driven by shared metabolic mechanisms. However, the metabolic perturbations linking MASLD and CVD remains unexplored in people living with HIV (PLHIV). Methods We investigated subjects from the longitudinal multicenter 2000HIV study (NCT03994835), which included 1895 virally suppressed PLHIV…
Background Men who have sex with men (MSM) on HIV pre-exposure prophylaxis (PrEP) have an increased risk of hepatitis C virus (HCV) infection. We assessed the impact of a test-and-treat campaign using HCV nucleic acid (NAT) and core antigen (cAg) testing in reducing the HCV incidence among MSM in the French ANRS PREVENIR study. Methods…
Background Persistent chronic HBV infection is associated with impaired functional T-cell specific responses and a lack of memory T-cells against core (C), polymerase (P), and envelope proteins (S). Therapeutic vaccination is aimed to relieve exhausted T-cells and to stimulate recall memory T-cells. We have developed an antigen-presenting cell (APC)-targeting approach allowing the delivery of specific…
Background Effective treatment of hepatitis B (CHBV) infection requires adherence to long-term daily antiviral therapies. These include oral tenofovir (TFV) prodrugs [TFV disoproxil-/TFV alafenamide-fumarate – TDF/TAF] or entecavir. Treatment cessation leads to HBV reactivation and disease progression. This underscores the need for long-acting formulations to improve treatment outcomes. Considering these needs, we developed a scalable amino…